Form 4: Halozyme CFO's Equity Vesting and Tax Withholding

Halozyme Therapeutics' CFO, Nicole LaBrosse, reported the vesting of restricted and performance stock units, along with corresponding share dispositions for tax obligations.

Summary

• Nicole LaBrosse, SVP, Chief Financial Officer of Halozyme Therapeutics, Inc. (HALO), reported transactions related to her equity compensation.
• On February 20, 2026, 5,332 Restricted Stock Units (RSUs) vested, resulting in the acquisition of 5,332 shares of common stock at an exercise price of $0.
• Concurrently, 2,876 shares were disposed of at a price of $70.98 to cover tax withholding obligations related to the RSU vesting.
• On February 23, 2026, 6,688 Performance Stock Units (PSUs) vested, leading to the acquisition of 6,688 shares of common stock at an exercise price of $0.
• An additional 3,608 shares were disposed of at a price of $70.64 on February 23, 2026, to satisfy tax withholding obligations for the PSU vesting.
• Following these transactions, Ms. LaBrosse beneficially owns 38,494 shares of Halozyme Therapeutics common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event for the executive, as it represents the realization of equity compensation. For the company, it is a neutral, routine administrative event related to executive compensation, reflecting standard practice rather than new operational or financial news.

Positives

• The vesting of 5,332 Restricted Stock Units and 6,688 Performance Stock Units represents a significant increase in the CFO's direct equity ownership in the company, demonstrating continued alignment with shareholder interests.
• The acquisition of shares at an exercise price of $0 indicates these were grants of equity compensation, which is a common and effective way to incentivize executive performance.

Negatives

• A total of 6,484 shares were disposed of across two transactions to cover tax withholding obligations, which is a necessary reduction in the gross number of shares received from vesting.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that the vesting of restricted and performance stock units, followed by a 'sell-to-cover' transaction for tax purposes, is a standard and routine practice for executives receiving equity compensation across various industries, particularly in the biotechnology and pharmaceutical sectors where long-term incentives are common.

Stakeholder Impact

• Shareholders: The transactions represent a routine aspect of executive compensation and do not directly impact the company's operational performance or financial health. The net increase in the CFO's direct ownership could be seen as a positive signal of alignment.
• Employees: No direct impact on the broader employee base is indicated by this filing.

Key Dates

Keywords

Halozyme Therapeutics, HALO, Form 4, Insider Transaction, Restricted Stock Units, Performance Stock Units, Equity Compensation, CFO, Stock Vesting, Tax Withholding